Treats multiple inflammatory nodules with a diameter of 5 mm or greater. ANDA 205063, held by Actavis Labs Fl. Isotretinoin.
As of Nov 16, 2026, ANDA 205063 (Isotretinoin), held by Actavis Labs Fl, was first approved by FDA on Mar 31, 2021, with 8 approved supplements and 0 published complete response letters.
Isotretinoin capsules are indicated for the treatment of severe recalcitrant nodular acne in non-pregnant patients 12 years of age and older with multiple inflammatory nodules with a diameter of 5 mm or greater. Because of significant adverse reactions associated with its use, isotretinoin capsules are reserved for patients with severe nodular acne who are unresponsive to conventional therapy, including systemic antibiotics. Limitations of Use If a second course of isotretinoin capsules treatment is needed, it is not recommended before a 2-month waiting period because the patient’s acne may continue to improve following a 15 to 20-week course of treatment.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 31, 2021 | Original application | Approved |
| Isotretinoin10MG · capsule;oral | Isotretinoin | Rx |
| Isotretinoin20MG · capsule;oral | Isotretinoin | Rx |
| Isotretinoin25MG · capsule;oral | Isotretinoin | Rx |
| Isotretinoin30MG · capsule;oral | Isotretinoin | Rx |
| Isotretinoin35MG · capsule;oral | Isotretinoin | Rx |
| Isotretinoin40MG · capsule;oral | Isotretinoin | Rx |
| Nov 3, 2026 | Supplement 14Labeling · Standard review | Approved | None posted |
| Oct 7, 2026 | Supplement 13REMS | Approved | None posted |
| Feb 9, 2026 | Supplement 10REMS | Approved | None posted |
| Jun 18, 2025 | Supplement 11Labeling · Standard review | Approved | None posted |
| Jun 3, 2025 | Supplement 8Labeling · Standard review | Approved | None posted |
| Mar 24, 2023 | Supplement 5REMS | Approved | None posted |
| Oct 6, 2022 | Supplement 4REMS | Approved | None posted |
| Oct 8, 2021 | Supplement 1REMS | Approved | None posted |
| Mar 31, 2021 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters